The small molecule 5-(4-phenoxybutoxy)psoralen (PAP-1) is a selective blocker of the voltage-gated potassium channel Kv1.3 that is highly expressed in cell membranes of activated effector memory T cells (TEMs). The blockade of Kv1.3 results in membrane depolarization and inhibition of TEM proliferation and function. In this study, the in vitro effects of PAP-1 on T cells and the in vivo toxicity and pharmacokinetics (PK) were examined in rhesus macaques (RM) with the ultimate aim of utilizing PAP-1 to define the role of TEMs in RM infected with simian immunodeficiency virus (SIV). Electrophysiologic studies on T cells in RM revealed a Kv1.3 expression pattern similar to that in human T cells. Thus, PAP-1 effectively suppressed TEM proliferation in RM. When administered intravenously, PAP-1 showed a half-life of 6.4 hrs; the volume of distribution suggested extensive distribution into extravascular compartments. When orally administered, PAP-1 was efficiently absorbed. Plasma concentrations in RM undergoing a 30-day, chronic dosing study indicated that PAP-1 levels suppressive to TEMs in vitro can be achieved and maintained in vivo at a nontoxic dose. PAP-1 selectively inhibited the TEM function in vivo, as indicated by a modest reactivation of cytomegalovirus (CMV) replication. Immunization of these chronically treated RM with the live influenza A/PR8 (flu) virus suggested that the development of an in vivo, flu-specific, central memory response was unaffected by PAP-1. These RM remained disease-free during the entire course of the PAP-1 study. Collectively, these data provide a rational basis for future studies with PAP-1 in SIVinfected RM.
Introduction
Voltage-gated potassium channels (Kv) regulate several physiologic functions of lymphocytes, including membrane potassium permeability, calcium influx, cytokine production, clonal expansion, and cell death (1) (2) (3) (4) . Although Kv1. 3 is found in all T-and B-cell subsets in the resting state, the expression is markedly upregulated in activated effector memory T cells (TEMs) and in Ig-class-switched memory B cells, in which they increase from approximately 250 to 1500 channels per cell (5, 6) . Naive T cells, central memory T cells (TCMs), and IgD þ B cells, in contrast, increase the expression of another potassium channel, the calcium-activated channel KCa3.1, upon cellular activation (1) . This differential expression of potassium channels provides an opportunity for selective inhibition of distinct cell subsets. Indeed, the KCa3.1-specific blocker TRAM-34 has been shown to preferentially suppress the proliferation of preactivated naive T cells, TCMs, and IgD þ B cells, whereas Kv1.3-specific blockers suppress the proliferation of activated human TEMs but not of naive T cells or TCMs when stimulated with the anti-CD3 monoclonal antibody or antigen in vitro (5) (6) (7) (8) . Manipulation of Kv1.3 expression or function therefore could have therapeutic potential for the treatment of diseases in which TEMs or class-switched memory B cells contribute to pathogenesis. In proof of this hypothesis, recent studies focusing on TEM-mediated autoimmune diseases have shown that Kv1.3-specific peptides, such as ShK and its derivative ShK(L5), effectively relieve experimental autoimmune encephalomyelitis and pristane-induced arthritis in rats (9) (10) (11) . However, because peptides administered in vivo risk inducing an immune response, particularly if chronic dosing is required, it was reasoned that a nonimmunogenic, smallmolecule Kv1.3 blocker, such as the recently reported 5-(4phenoxybutoxy)psoralen (PAP-1), would be more practical.
PAP-1 is a synthetic derivative of the natural product 5methoxypsoralen and has been shown to exhibit a 23-to 125-fold selectivity for Kv1.3 compared with other members of the Kv1 family, effectively blocking Kv1.3 with a 50% effective concentration (EC 50 ) of 2 nM and a stoichiometry of two inhibitor molecules per channel (7) . PAP-1 has been shown to inhibit the in vitro proliferation of human CCR7 À TEMs significantly more potently than the proliferation of naive T cells and TCMs and to effectively suppress delayed-type hypersensitivity (DTH) in rats, a response that is mediated primarily by skin-homing CD4 þ TEMs (7) . In addition, PAP-1 delayed diabetes onset and reduced diabetes incidence in spontaneously diabetic BB/ Worchester rats at doses that did not exhibit any toxicity (11) . Thus, the selective effect of PAP-1 for TEMs does not limit its application to only autoimmune diseases but also provides the potential for the treatment of other ailments in which TEMs play a major pathogenic role.
Activated memory CD4 þ T cells have been shown to be the primary targets for human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) infection, which results in chronic T-cell hyperactivation that contributes to CD4 þ T-cell apoptosis, early immune dysfunction, and eventual exhaustion of the virus-specific immune response, ultimately leading to disease and death (12) (13) (14) (15) (16) (17) . These antigen-specific, memory CD4 þ T cells are theoretically derived from antigen-activated, naive T cells that differentiate into central and effector T cells (18, 19) . SIV infection of nonhuman primates such as rhesus macaques (RM; Macaca mulatta) cause a disease course remarkably similar to HIV-1 infection of humans (13, 20) , making this species an ideal model for the study of the effect of PAP-1 on SIV pathogenesis and to determine its potential to alter viral replication and disease course in vivo. The hypothesis is whether the administration of PAP-1 in SIV-infected RM prevents or slows disease progression by limiting the expansion of activated memory viral target cells and/or by contributing to the muting of the chronic immune activation response via inhibition of TEM function. Conversely, the suppression of a virus-specific, effector T-cell response could also have detrimental effects on the control of viral replication and may accelerate the course of infection. Thus, investigating the influence of PAP-1 on SIV pathogenesis will help define cell lineages and/or mechanisms that are involved in the protection or deterioration of the immune system following SIV infection in this species. Before such a task is undertaken, it is vital to first assess both the in vitro and in vivo effects of PAP-1 in RM. The goal of this study was to determine the potential toxicity, if any, and the pharmacokinetics (PK) of PAP-1 in healthy, uninfected RM in order to determine a therapeutic dose of PAP-1 that could be used in SIV-infected animals in the future. A single dose of PAP-1 was initially administered to RM and, upon determination of the safety and PK, a chronic dosing study was initiated to determine the dosage required to maintain a critical trough level of this compound. RM undergoing chronic PAP-1 dosing were also infected intranasally with a live attenuated influenza A/PR8 (flu) virus and the effect of PAP-1 on the primary effector and the secondary memory flu-specific responses were assessed in order to confirm the target-cell selectivity of PAP-1 in vivo. In parallel with these in vivo studies, in vitro experiments were performed to define the Kv1.3 channel expression profile in T-cell subsets in RM and to determine the potential in vitro suppressive effect of PAP-1 on activated TEMs in RM. Results suggest that PAP-1 was both safe and effective in vitro and in vivo, which provides a rational and sound foundation for future studies with PAP-1 in SIV-infected RM.
Materials and Methods
Animals. Healthy, SIV-negative RM of comparable age and weight were housed at the Yerkes National Primate Research Center of Emory University. Their housing, care, diet, and maintenance were in conformance to the guidelines of the Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council and of the Health and Human Services by the standard guidelines, ''Guide for the Care and Use of Laboratory Animals'' (21). RM were anesthesized with 10 mg/kg of ketamine hydrochloride that was administered intramuscularly. For acute PAP-1 dosing experiments that required multiple bleeds at frequent time intervals, anesthesia was administered every 2-4 hrs as needed. On days when only a single bleed was required, a single dose of ketamine was administered prior to sample retrieval. RM that were immunized with the flu virus for the chronic dosing study were anesthesized and were intranasally administered 1 ml of solution that contained 1024 hemagglutinin antigen (HA) units of the virus in a slow, drop-by-drop fashion, as described elsewhere (22) . The animals were also boosted 4 weeks and 12 weeks after the initial immunization with the same viral dose and by the same route of administration.
PAP-1. PAP-1 was synthesized as previously described (7) . For the in vitro assays, PAP-1 was dissolved in dimethylsulfoxide (DMSO) to a concentration of 10 mM, and this stock solution was diluted to desired concentrations using RPMI-1640 medium that was supplemented with 1% fetal calf serum (FCS), 2 mM glutamine, and 50 lg/ml gentamycin. The final DMSO concentration in the culture assays was 0.05%. For intravenous administration, PAP-1 was dissolved at a concentration of 9 mg/ml in a mixture of cremophor (Sigma-Aldrich, St. Louis, MO) and 13 phosphate-buffered saline (PBS; 1:4) by heating to approximately 908C and then vigorously stirring. Aliquots of the cooled PAP-1 solution were frozen at À208C until use. For oral administration, PAP-1 was mixed at a final dosage of 25 mg/kg for each animal into approximately 5 g of chocolate paste just prior to administration and the stock was stored at 48C for no more than a week before being fed to the animals.
Specimen Collection and Toxicity Analyses. Whole blood was collected from the RM in heparinized tubes for the determination of absolute counts of white blood cells (WBCs), platelets, and the total lymphocyte count using standard methods. In addition, sera were evaluated for the levels of albumin, liver enzymes, bilirubin, blood urea nitrogen/creatinine, and various electrolytes, using our standard in vivo toxicology screen. Peripheral blood mononuclear cells (PBMCs) were also isolated from heparinized whole blood by standard Ficoll-Hypaque gradient centrifugation.
Determination of Plasma PAP-1 Levels by High-Performance Liquid Chromatography (HPLC)-Mass Spectroscopy. PAP-1 was injected intravenously or was administered orally to two rhesus macaques (12 and 17 kg, respectively). At various time points following administration, approximately 0.5 ml of blood was collected into EDTA-blood sample collection tubes. Plasma was separated by centrifugation and was stored at À208C, pending analysis. Samples were purified using C18, solid-phase extraction (SPE) cartridges. Elution fractions corresponding to PAP-1 were evaporated to dryness under nitrogen and were reconstituted in a 2:3 mixture of acetonitrile (ACN) and water. Liquid chromatography electrospray ionization tandem mass spectrometry analysis was performed with a Hewlett-Packard 1100 series HPLC stack that was equipped with a KGaA RT 250-4 LiChrosorb RP-18 column (Merck, Darmstadt, Germany) and an HP 1100 variable-wavelength detector (VWD) and was interfaced to a Finnigan LCQ Classic Mass Spectrometer (MS; Thermo Fisher Scientific, Waltham, MA). The mobile phase consisted of ACN:H 2 O with 0.2% formic acid. The flow rate was 1.0 ml/min, and the gradient was ramped from 1:1 to 9:1 ACN:H 2 O over 20 mins. While the column temperature was maintained at 248C, PAP-1 was eluted at 14.8 mins and was detected with the VWD and the MS in series. Quantitation was performed by electrospray ionization MS/MS (capillary temperature ¼ 3508C; capillary voltage ¼ 5 V; tube-lens offset ¼ À25 V; positive-ion mode; normalized collision energy ¼ 25.7%; parent mass ¼ 351.1 m/z; SRM ¼ 107.0, 149.0, 251.0, 351.2) for samples between 2.5 nM (0.88 ng/mL) and 750 nm (263 ng/mL) and by the VWD (310 nm) for samples with higher concentrations. The related compound 5(4phenoxypropoxy)psoralen (PAP-3; formula weight ¼ 336.33; RT ¼ 13.5 mins) was used as an internal standard.
The pharmacokinetics of the data obtained on samples following intravenous injection were plotted as a twocompartment model, using both Origin (Rockware Inc., Golden, CO) and Winnonlin software (Pharsight, Mountain View, CA).
Flow Cytometry Analysis. Aliquots of the PBMCs were subjected to standard immunophenotypic analysis to determine the frequencies of major T-cell subsets, including naive cells, TCMs, TEMs, and regulatory T-cells (Tregs), using the following antibody clones: CD4-PerCP (clone L200), CD8-FITC (clone SK1), CD28-PE (clone 28.2), and CD95-APC or -FITC (clone DX-2), all purchased from BD Pharmingen (San Diego, CA); CD25-PE (clone 4E3; Miltenyi Biotec, Auburn, CA); and FoxP3-APC (clone PCH101; eBioscience, San Diego, CA). To phenotypenaive, TCM, and TEM subsets, cells were first incubated with 1 lg/ml of anti-FcR antibody (clone 2.4G2; courtesy of Dr. R. Mittler, Emory University Center for AIDS Research) for 15 mins at 48C, were washed, and then were surface-stained for 15 mins at 48C with predetermined optimal concentrations of CD4-PerCP, CD8-FITC, CD28-PE, and CD95-APC. Cells were washed, resuspended in freshly prepared 1% paraformaldehyde in PBS (pH 7.4) and were analyzed. T-cell subsets were defined as naive (CD28 þ CD95 À ), TCM (CD28 þ CD95 þ ), and TEM (CD28 À CD95 þ ; Ref. 23 ). In the Treg phenotypes, cells were surface-stained in a similar manner, using CD4-PerCP and CD25-PE. Fixation and intracellular staining to detect FoxP3 were performed according to eBioscience protocol. Appropriate monoclonal antibody-isotype controls were included. Flow-cytometric acquisition of at least 100,000 total events from each sample was performed on a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA). Data acquisition and analysis were performed using CellQuest (BD Biosciences) and FlowJo (TreeStar, Ashland, OR) software, respectively.
Proliferation Assays. PBMCs were isolated from the peripheral blood of healthy RM (n ¼ 9) and were resuspended in RPMI at a concentration of 1,000,000 cells/ ml. One hundred microliters of solution that contained 100,000 cells were dispensed into each well of a 96-well polystyrene plate that was previously coated overnight with 400 ng/ml of anti-CD3 monoclonal antibody (clone FN-18; Biosource, Invitrogen, Carlsbad, California). PAP-1 was added in a volume of 100 ll of RPMI at increasing concentrations. Cultures were performed in triplicate. For the isolation of CD28 À effector memory cells, PBMCs were incubated with anti-CD28-coated magnetic beads (Dynal Cellection Kit; Invitrogen) for 30 mins at 48C with gentle rotation. CD28 þ cells bound to the beads were separated (5 mins 3 2) using a magnet, and the supernatant containing CD28 À cells was washed twice with 1% RPMI. An aliquot of these isolated cells was subjected to flow analysis, and the purity of the CD28 À cell population was always greater than 90%. The negatively isolated CD28-fraction was seeded at 100,000 cells/well in the absence or presence of increasing concentrations of PAP-1. Cultures were incubated at 378C and 7% CO 2 for 3 days, and cells were pulsed with [ 3 H]-thymidine (1 lCi/well) at 16 hrs prior to harvest. Cells were harvested onto glass-fiber filters, and the mean uptake of [ 3 H]-thymidine was determined using a standard b-scintillation counter.
Electrophysiology. Electrophysiologic studies were conducted on aliquots of both resting and in vitro activated, unfractionated and fractionated T-cell subsets. The T cells were isolated from PBMCs by negative selection, using an RM-specific T-cell enrichment kit (StemCell Technologies Inc., Vancouver, Canada). Aliquots of the isolated T cells were activated with 10 lg/ml of plate-bound anti-CD3 (clone FN-18; BioSource/Invitrogen) for approximately 40 hrs. Both resting and in vitro, activated T cells were stained for CD28 and CD95 on ice in an RPMI medium (supplemented with 10% FCS and 0.1% NaN 3 ) with phosphatidylethanolamine (PE)-conjugated mouse anti-human CD28 monoclnal antibody (CD28.2; BD Pharmingen) and FITC-conjugated mouse antihuman CD95 monoclonal antibody (DX2; BD Pharmingen). Cells were washed, were incubated on poly-L-lysine-coated coverslips, and were kept in the dark at 48C for 10-30 mins to allow attachment. Naive cells (CD28 þ CD95 À ), TCMs (CD28 þ CD95 þ ), and TEMs (CD28 À CD95 þ ) were visualized by fluorescence microscopy and were studied in the whole-cell configuration of the patch-clamp technique.
Kv1.3 currents were elicited in situ by repeated 200-ms pulses from a holding potential of À80 mV to 40 mV, which were applied either every second to visualize the characteristic cumulative inactivation of Kv1.3, or every 30 secs in experiments to measure the blocking activity by ShK(L5) or PAP-1 on Kv1.3 currents. Currents were recorded in normal Ringer's solution with a calcium-free pipette solution that contained the following: 145 mM KF, 10 mM HEPES, 10 mM EGTA, and 2 mM MgCl 2 (pH 7.2; 300 mOsm). Wholecell Kv1.3 conductance measurements were calculated from the peak current amplitudes at 40 mV. KCa3.1 currents were elicited with voltage ramps from À120 mV to 40 mV of 200 msecs duration, which were applied every 10 secs with a pipette solution containing the following: 145 mM potassium aspartate, 2 mM MgCl 2, 10 mM HEPES, 10 mM K 2 -EGTA, and 8.5 mM CaCl 2 (1 lM free calcium; pH 7.2; 290 mOsm). To reduce chloride leak currents, we used a sodium aspartate, external solution containing the following: 160 mM sodium aspartate, 4.5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM HEPES (pH 7.4; 300 mOsm). Kv1.3 and KCa3.1 channel numbers per cell were determined by dividing the whole-cell Kv1.3 or KCa3.1 conductance by the single-channel conductance value for each channel-Kv1.3: 12 pS; IKCa1: 11 pS. Cell capacitance, a direct measure of cell surface area, was constantly monitored during recording. Resting (unstimulated) T cells had membrane capacitances less than 2 pF (average cell diameter , 7 lm), whereas activated cells had membrane capacitances greater than 4 pF (average cell diameter . 11 lm).
Real-Time Polymerase Chain Reaction (PCR) for Rhesus Cytomegalovirus (RhCMV) Quantification. A real-time PCR assay was performed to quantify RhCMV DNA copy numbers in plasma samples from the RM undergoing the PAP-1 chronic dosing study by measuring levels of the pp65 virus sequence. The template for the reaction was total viral DNA, isolated from the plasma samples using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA). Each plasma sample was spiked with an equal amount (10,000 copies) of an unrelated plasmid that contained the chloramphenicol acetyl transferase (CAT) sequence to control for the efficiency of DNA extraction. These were later subjected to and were quantified by PCR using CAT-specific primers, as described before (24, 25) , to serve as an internal control by confirming uniformity in DNA isolation from each plasma sample. The forward primer (59-GTTTAGGGAACCGCCATTCTG-39) corresponded to residues 719-739, and the reverse primer (59-GTATCCGCGTTCCAATGCA-39) corresponded to residues 826-808 (26) . Reactions of a 20-ll total volume containing 13 iQ SYBR Green Supermix (BioRad), 100 ng/ ll of each primer, nuclease-free water, and the template from each plasma sample were prepared in duplicate. PCR was performed on an iCycler (BioRad, Hercules, CA) under the following conditions: 10 mins at 958C followed by 45 cycles of 15 secs at 958C and of 1 min at 608C. A standard curve was generated by using 10-fold serial dilutions of a control, pGEM-T plasmid containing the pp65 target sequence (10 6 -0 copies per reaction). Results were analyzed using the iCycler iQ Optical System software (BioRad), and the limit of sensitivity was reproducibly between 1-10 copies of the template.
Determination of Flu-Specific, Cell-Mediated, and Humoral Responses. For determination of CD4 þ and CD8 þ T-cell responses, aliquots of PBMCs from each monkey were cultured for 2 hrs with whole-flu virus (approximately 100 HA units/well), ConA (positive control; 7.5 lg/ml), or OVA peptide (negative control; 3 lg/ml) followed by the addition of brefeldin A (6 lg/ml) and incubation overnight at 378C and 5% CO 2 . Cells were washed and were surface-stained with CD4-PerCP and CD8-FITC (BD Pharmingen) and then were fixed/permeabilized and were stained for intracellular IFN-c-APC or for IL2-APC and TNF-a-PE (all from BD Pharmingen). The frequency of cytokine-producing, CD4 þ or CD8 þ cells was determined by standard flow cytometric analysis on the FACS Calibur II (BD Biosciences). For determination of humoral responses, a standard enzyme-linked immunoabsorbant assay (ELISA) to detect flu-specific IgG was performed. Briefly, 96-well plates were coated with poly-L-lysine and, whole-flu virus was dispensed into individual wells overnight. The plates were washed, and media containing 2% non-fat milk solution was added for blocking non-specific binding. The 100 ll of plasma to be assayed was diluted to 1:100, 1:1000, 1:5000, 1:10000, and 1:50000 in 10% RPMI, which then were added in triplicate wells. Plates were incubated at 378C for 2 hrs and washed four times with PBS-T. Then, 100 ll of 1:2000 diluted alkalinephosphatase-conjugated antihuman Ig (Southern Biotech, Birmingham, AL) was added to each well. After a 1-hr incubation at 378C, wells were washed, and the reaction was developed using an alkaline phosphatase substrate kit (BioRad, Hercules, CA). Wells were monitored for color development, and absorbance was measured at 405 nm. The cut-off value was determined as the mean of the negative control plus three times its standard deviation (SD). Samples with mean absorbance readings exceeding this value were considered positive for the presence of flu-specific IgG, and the reciprocal of the highest dilution of plasma that gave a positive reaction was considered the titer in the sample being tested.
Statistical Analyses. Data are represented as mean 6 SD unless otherwise indicated. Any statistical analyses to determine significant differences were derived using the two-tailed Student's t test. A P less than 0.05 was considered statistically significant.
Results

Kv1.3 Expression in RM T Cells is Comparable
to Levels Present in Human T Cells. Prior to investigating the in vivo and in vitro effects of PAP-1 in RM, it was essential to first determine if RM resemble humans and express Kv1.3 and KCa3.1 in a T-cell subsetspecific manner. Because there are currently no specific antibodies to Kv1.3 or KCa3.1 suitable for use in flow cytometry, a combination of fluorescence microscopy and electrophysiology were utilized to study potassium-channel expression in RM, as was previously done in human T cells (5) . CD3 þ lymphocytes were isolated by negative selection from PBMCs of healthy RM (n ¼ 6); both resting and anti-CD3 activated T cells were stained with CD95-FITC and CD28-PE to distinguish among naive, TCM, and TEM subsets and their potassium currents were measured in the whole-cell mode of the patch-clamp technique. Each subset expressed Kv currents, which were confirmed to be Kv1.3 by their biophysical and pharmacologic properties. The currents exhibited the Kv1.3 characteristic use-dependence upon rapid pulsing, and they showed the same inactivation time constant (approximately 200 ms; Fig. 1A ) and halfactivation voltage (V 1/2 ¼ À33 mV; Fig. 1B ) as the cloned channel (27) . Furthermore, the Kv current in all three T-cell subsets was inhibited by the Kv1.3-specific blockers ShK(L5) and PAP-1, with 50% inhibitory concentrations (IC 50 s) of 72 pM and 2.1 nM, respectively. See Figures 1C and 1D for representative recordings and Figure 1E for the concentration-response curves. The Kv1.1-specific peptide DTX-1 had no effect on the current at a concentration of 100 nM, demonstrating that, in contrast to mouse T cells, T cells in RM do not express functional Kv1.1 channels. See Figure  1C for a representative recording from a resting naive T cell. In addition to Kv1.3 currents, we also detected calciumactivated potassium currents that exhibited the biophysical and pharmacologic characteristics of KCa3.1 in T cells of RM when dialyzing 3 lM of free calcium through the recording pipette. The currents reversed around À80 mV and were sensitive to blockade by the specific KCa3.1 blocker TRAM-34 ( Fig. 1F ).
In addition, the numbers of Kv1.3 and KCa3.1 channels in naive cells, in TCMs, and in TEMs were also determined by patch-clamping roughly 20 cells from each subset in both the resting and activated state and then by dividing the whole-cell Kv1.3 or KCa3.1 conductance by the single channel conductance value for each channel (see Figure 2A for representative Kv1.3 and KCa3.1 currents). Although the number of Kv1.3 channels is generally slightly lower in RM than in human T-cells (5), the expression pattern is very similar. As seen with naive cells and TCMs in humans, the upregulation of Kv1.3 channels in these cell subsets in RM was minimal upon activation; however, as anticipated, activated TEMs from RM exhibited a significant (approximately 8-fold) increase in Kv1.3 channels similar to the level of upregulation that occurs in activated human TEMs. In contrast, there was an approximately 30-to 40-fold increase in the number of KCa3.1 channels in activated naive cells and TCMs, with no upregulation occurring in the TEM subset. The differential upregulation of these potassium channels among the T-cell subsets was reflected by the increase in Kv1.3 and KCa3.1 currents in activated TEM cells and in naive cells or TCMs, respectively ( Fig. 2A) . Staining with the CD95 and CD28 antibodies did not interfere with the expression pattern of Kv1.3 and iKCa3.1 currents (data not shown). Taken together, these data indicate that Kv1.3 and KCa3.1 are the only potassium channels expressed in T cells of RM and that their expression pattern is similar to human T cells. Although KCa3.1 is the dominating channel in activated naive cells and in TCMs, activated TEMs express a Kv1.3 high phenotype.
PAP-1 Inhibits the Proliferation of RM PBMCs and TEM Cells in vitro. Recent studies demonstrated that Kv1.3 expression in human T cells is low in both CD4 þand CD8 þ -naive cells and in TCMs; expression is high in both activated CD4 þ and CD8 þ CCR7 À TEMs (7) . As a result, PAP-1 effectively suppressed the proliferation of human CCR7 À TEMs in vitro, with an IC50 of 10 nM (7) . It was reasonable to assume that the same would be true in RM, and we therefore evaluated the effect of PAP-1 on total CD28 À T cells, because TEMs in RM are best defined by the CD28 À CD95 þ phenotype (23) . Thus, to determine if a comparable degree of suppression was observed with TEMs in RM, an in vitro assay was performed in which CD28 À TEMs were negatively isolated from PBMCs in RM (n ¼ 9) using anti-CD28-coated magnetic microbeads. Negatively isolated cells were confirmed to be 90% CD28 À by flow cytometry. This CD28 À fraction, containing primarily the TEM subset, was stimulated in vitro with a low, suboptimal concentration of plate-bound anti-CD3 in order to preferentially activate TEMs, which exhibit a lower activation threshold than naive cells or TCMs (28) . As shown by the representative data in Figure 3 , PAP-1 suppressed the proliferation of TEMs with an IC 50 of approximately 100 nM. The suppressive effect of PAP-1 on bulk PBMCs, which predominantly consist of naive cells and TCMs, was also tested and was found to be less pronounced with an IC 50 of approximately 1 lM (Fig. 3 ). Isolated CD28 þ T cells could not be utilized as a pure source of naive cells and TCMs, because the T cells still contained bound anti-CD28 antibody when released from the magnetic beads. This in combination with anti-CD3 resulted in a level of stimulation that abrogated the suppressive effect of PAP-1. This observation is in line with a previous study which reported that T cell proliferation was unaffected by the potassium channel blocker margatoxin when costimulation with anti-CD28 was involved (4). In summary, the results obtained suggest that PAP-1 is an effective inhibitor of TEM proliferation in RM, which is consistent with previous studies.
Acute In Vivo Dosage Studies Suggest that PAP-1 Is Non-Toxic and that Its PK Is Best Reflected by a Two-Compartment Model. To determine the in vivo toxicity and PK of PAP-1, two adult RM, RHg7 and RVe7, were administered the compound intravenously at a dose of 3 mg/kg. The intravenous administration of PAP-1 was well tolerated by both animals with no signs of acute side effects. Blood and serum biochemical parameters were determined at 48 hrs and at 7 days postadministration, and comparison with baseline levels suggested no evidence of PAP-1-related hematologic and organ toxicity (Table 1 ). An increase in the levels of serum creatinine phosphokinase (CPK) from baseline levels was observed in both RM, but this was attributed to the effect of the anesthetic ketamine hydrochloride that was used to sedate the animals for blood sample collection. Ketamine anesthesia and the physical restraint associated with its administration have been shown to induce variations in several serum and hematologic parameters in nonhuman primates, including RM and cynomologus monkeys (29, 30) . Indeed, repeated ketamine administration that was necessary for multiple blood sample withdrawal within the first 48 hrs of the acute PAP-1 dosing experiment led to alterations in CPK activity and to fluctuations in other biochemical variables, such as glucose and aspartate transaminase (AST), in both RHg7 and RVe7. A decrease in circulating lymphocytes with a coincident increase in neutrophils was also observed, as previously described, which suggests a redistribution of lymphocytes from the blood to extravascular sites and a mobilization of neutrophils to the peripheral circulation. Further analysis of PBMCs for the frequencies of major T-cell subsets, Figure 3 . PAP-1 suppresses the proliferation of PBMCs and TEMs from RM. PBMCs isolated from healthy, uninfected RM (n ¼ 9) were seeded at 100,000 cells/well and were stimulated with 400 ng/ml, plate-bound anti-CD3 in the absence or presence of increasing concentrations of PAP-1 (nM). To test the effect of PAP-1 on TEMs, PBMCs were depleted of CD28 þ cells using anti-CD28-coated magnetic microbeads, and the CD28 À fraction was seeded at 100,000 cells/well. Cultures were incubated at 378C and 7% CO 2 for 3 days. Cells were pulsed with 1 uCi/well [ 3 H]-thymidine at 16 hrs prior to harvest, and thymidine uptake was measured by standard scintillation counting. The mean cpm 6 SD was determined; data shown is representative of three independent assays.
including CD4 þ and CD8 þ naive cells, TCMs, TEMs, and CD4 þ Tregs, by flow cytometry also reflected this decrease in lymphocytes at the 8-hr time point (Table 2 ). However, the levels of circulating lymphocytes and serum analytes returned to values near baseline within a week (Tables 1 and  2 ).
The PK of intravenously administered PAP-1 was also examined in each of the two animals. Plasma samples were collected before and at a number of time points (15 mins, 30 mins, 1 hr, 2 hrs, 4 hrs, 8 hrs, 24 hrs, 48 hrs and 7 days) after PAP-1 administration. PAP-1 plasma concentrations at each time point were determined by HPLC-MS, and the data obtained appeared to be a two-compartment model that followed second-order kinetics (Fig. 4A, left panel) . The rate of elimination of PAP-1 was moderately slow, with an in vivo half-life of 6.4 hrs. The volume of distribution ( Fig  4A, right panel) was between 2-4 l/kg, which is similar to the level previously determined in rats, although the half-life of PAP-1 in these rodents is shorter (3.8 hrs; Ref. 11).
After a washout period of approximately 2 months, and upon confirmation of normal baseline levels of blood/serum chemistry parameters, the safety and efficacy of orally administered PAP-1 (25 mg/kg) was determined in the same two RM. As depicted in Figure 4B , the plasma concen-tration of PAP-1 peaked within 10 hrs of ingestion and reached a maximum of approximately 1700 nM and approximately 950 nM in RHg7 and RVe7, respectively. This indicated an efficient absorption of PAP-1 via the oral route. There were no signs of toxicity evident in the RM following oral administration of PAP-1. In addition, and similar to the intravenous acute dosing results, fluctuations in serum and hematologic parameters were observed in the 48-hr blood/serum samples after initial ketamine administration, but all values returned to baseline levels within a week (data not shown).
Chronic Dosing of PAP-1 in RM Immunized with the Flu Virus Does Not Appear to Increase Their Susceptibility to Infection and Selectively Inhibits TEM Function but Not the Development of a Central Memory Flu-Specific Response. Because results of the acute dosing studies indicated that there were no detectable toxic side effects at the dose utilized during and following in vivo PAP-1 administration, a 30-day chronicdosing study was initiated in two RM, RGq8 and RWk7. The protocol utilized is outlined in Table 3 . The purpose of this experiment was threefold. First, it was necessary to assess the safety of chronic administration of PAP-1 and to determine the dose required to maintain a critical trough level of the compound in RM in vivo. Second, given that all TEMs and not just antigen-specific TEMs upregulate Kv1.3 channels upon activation, the possibility exists that PAP-1 may globally suppress TEMs and may compromise the host's ability to respond to pathogens. It was therefore critical to ensure that chronic application of PAP-1 does not result in increased susceptibility of the host to opportunistic infection or disease. Finally, the main feature of PAP-1 is that it selectively inhibits the function of TEMs, as shown by previous studies and by the in vitro data herein (Fig. 2) . It was therefore important to demonstrate that this selectivity holds true in vivo.
To accomplish the aforementioned tasks, a chronic dosing study was initiated by administering PAP-1 orally to the two RM daily for a 30-day period at a dosage of 25 mg/ kg/day. The oral route was chosen because of logistic limitations of daily intravenous administration, because of the ease of administration, and because pharmacologically relevant levels of PAP-1 were readily detectable in the plasma. The elimination of PAP-1 in RM was previously determined to be relatively slow with a half-life of 6.4 hrs, so the dose was administered once daily. Blood samples were collected at baseline and before each feeding, at the indicated time points (Table 3 ) and were utilized to determine standard blood/serum chemistry, and served as a source of PBMCs for the analysis of major T-cell subsets by flow cytometry. As seen with the acute-dosing study, chronic oral administration of PAP-1 did not result in any apparent hematologic and organ toxicity, and no marked fluctuations in the frequencies of major T-cell lineages were noted (not shown). Plasma samples were also isolated from the collected blood samples for analysis of PAP-1 concentrations by HPLC-MS. As shown by the results in Table 4 , trough levels with concentrations averaging 511 6 113 nM in RGq8 and 77 6 5 nM in RWk7 were maintained throughout the study, which suggested variations in individual uptake levels but also reproducibility within the same individual. After PAP-1 was discontinued, plasma levels decreased according to the established second-order kinetics, and low detectable levels were still present 17 days after PAP-1 was discontinued.
The selective suppressive effect of PAP-1 on TEMs in vivo was tested by measuring a potential (but clinically silent) reactivation of cytomegalovirus (CMV) replication by quantifying the levels of CMV DNA in plasma samples from these two RM by real-time PCR. Because CMV levels are believed to be kept in check by TEMs (26, 31) , a loss of TEM function was hypothesized to compromise the control of CMV replication. Total viral DNA was isolated from plasma samples of each monkey at various time points before, during, and after PAP-1 treatment. Prior to DNA isolation, these plasma samples were also spiked with an equal concentration of a control plasmid, containing the CAT sequence that was later quantified by real-time PCR to ensure consistency in DNA isolation from each sample (data not shown). Quantification of RhCMV revealed that at the baseline time point, both monkeys exhibited detectable, low levels of circulating CMV DNA (approximately 500-1000 copies/ml), which was unexpected (Fig. 5 ). These RhCMV levels remained relatively near baseline during the first 2 weeks of treatment but an increase did occur as indicated by the peak on Day 21 in both monkeys, with a larger increase being detected in samples from RWk7 (approximately 8800 copies/ml) than from RGq8 (approximately 2200 copies/ ml). After PAP-1 was discontinued, RhCMV levels rapidly returned to levels near baseline in both animals.
To further demonstrate the in vivo selectivity of PAP-1, both RM were immunized with the flu virus on Day 7, to determine if PAP-1 selectively inhibits the initial flu-specific effector T-cell response but not the development of central memory T-cells. In order to determine the functional nature of the TEM response, the cell-mediated, T-cell immune responses to the flu virus were measured by intracellular cytokine staining (ICC). The frequency of CD4 þ and CD8 þ T cells that produce the Th1 cytokines IFN-c, TNF-a, and IL-2 in response to whole-flu virus were determined. As expected, CD4 þ and CD8 þ T cells from both animals on Day 0 exhibited a minimal response to the OVA peptide (negative control), whereas ConA (positive control) induced a substantial increase in the level of all three cytokines tested (Fig. 6A ). Similar control data were observed for samples obtained on Days 28 and 47 (data not shown). In both RM, background levels of flu-specific T-cell responses were observed on Day 28 (3 weeks after the initial flu immunization), indicating that neither animal exhibited a Tcell response while being treated with PAP-1 (Fig. 6B ). This was unlike historical controls, in which early flu-specific Tcell responses are clearly evident (32) . However, on Day 47, 10 days after the first flu booster and 2 weeks after the discontinuation of PAP-1 treatment, a substantial and significant increase (P , 0.05) in the production of IFN-c and TNF-a by CD4 þ T cells (approximately 3% and 2.5% of CD4 þ T cells, respectively) was evident in RWk7, the animal which had cleared PAP-1 from the circulation by that time point. Increases in IL-2-producing CD4 þ T cells and in cytokine-producing CD8 þ T cells were also noted in this animal. Unlike RWk7, only a modest increase in the fluspecific, T-cell response was evident in RGq8 after the first flu booster, which was administered at a time when this animal still had marked levels of PAP-1 present in its system. The cytokine responses in RWk7 and RGq8 were comparable to or greater than those noted for historical controls (n ¼ 4) that were not treated with PAP-1 at any time and that exhibited an approximately 2-fold increase in the frequency of IFN-c-producing CD4 þ T cells (1.44% 6 0.35-3.25% 6 0.35) and CD8 þ T cells (0.42% 6 0.13-0.98% 6 0.10) following a primary flu booster approximately 46 days after the initial flu immunization (Ansari et al., unpublished data). A second flu booster was administered 2 months later to RWk7 and RGq8, and PBMC samples were analyzed 10 days thereafter. Similar results were obtained, in that a greater flu-specific response was exhibited by RWk7 than by RGq8 (data not shown). Next, the humoral flu-specific immune response in the plasma from these two monkeys was measured using our labstandardized ELISA. Anti-flu IgG levels in a series of diluted plasma samples from both animals were determined at baseline, at Day 21 (post-initial immunization), at Day 47 (10 days after first booster), and at Day 103 (10 days after second booster). As shown by the antibody titers in Table 5 , both animals exhibited a minimal, flu-specific antibody response while undergoing PAP-1 treatment. Similar to the pattern observed with ICC results, a response was only evident in RWk7 and not in RGq8 after the first booster, but both animals exhibited a strong humoral response after the second flu booster, as indicated by the flu antibody titer of 1:10000. As controls, three additional RM were immunized twice with the flu virus but were not administered PAP-1 at any time. Plasma samples were tested for the presence of flu antibody at time points comparable to those of the PAP-1- treated RM. As shown in Table 5 , all three control animals exhibited a flu-specific response after the first flu booster, but of particular significance is the fact that a response was already readily detectable in all three control RM 4 weeks after the initial immunization in contrast to the minimal or lack of response in the PAP-1-treated RM. Importantly, neither RGq8 nor RWk7 was adversely affected by the live flu immunization and neither exhibited other signs of disease during the entire course of the PAP-1 chronic dosing experiment.
Discussion
In order to delineate the role of different nonhuman primate lymphoid subset cells in the pathogenesis of SIV infection, our laboratory has been working to identify reagents that can selectively inhibit or deplete certain subsets. Here, we evaluated the toxicity and PK of the recently developed small molecule PAP-1 in RM in order to determine a safe and effective dose for future studies aimed at identifying the role of TEMs in the pathogenesis of SIV infection. PAP-1 and the peptide ShK(L5) have been previously shown to preferentially inhibit human and rat TEMs in vitro by blocking Kv1.3 in TEMs and to effectively suppress or treat delayed-type hypersensitivity, allergic contact dermatitis, experimental autoimmune encephalomyelitis, pristane-induced arthritis, and type-1 diabetes in rat models (7, 9, 11, 33) . Since activated CD4 þ TEMs are the primary targets for SIV infection, it was reasoned that the use of PAP-1 in SIV-infected RM would shed light on the role of this important cell lineage in disease progression or resistance. However, prior to conducting such intricate studies in SIV-infected RM, a comprehensive set of in vitro and in vivo experiments were first performed to determine the safety and efficacy of PAP-1 in healthy RM. PAP-1 had been previously reported to exhibit a 23-to 125-fold selectivity over the closely related Kv1-family channels expressed in the heart (Kv1.5 and Kv1.7) and in neurons and to exhibit a more than 1000-fold selectivity over HERG, sodium, calcium, and chloride channels (7) . PAP-1 further did not show any acute or chronic toxicity in rats (33) . However, PAP-1 had never before been used in primates, so we needed to determine if it could be safely used in RM. We further needed to ascertain whether RM express high levels of Kv1.3 in activated TEMs, similar to humans and rats (5, 10) . This could not simply be assumed, because ion channels often show significant species differences in their expression patterns. For example, besides Kv1.3 and KCa3.1, mouse T cells express Kv1.1, Kv1.2, and Kv1.6 in CD4 þ T cells and Kv3.1 in CD8 þ T cells; also, they do not upregulate Kv1.3 in TEMs (34-36). Kv1.3 blockers therefore do not inhibit mouse T-cell function in vitro (34) and have no effect in mouse autoimmune disease models (37) .
Our patch-clamping experiments clearly demonstrated that the potassium channels in T cells of RM are Kv1.3 and KCa3.1. Importantly, of these two channels, Kv1.3 was the one selectively upregulated in activated TEMs, whereas KCa3.1 expression was instead increased in activated naive cells and in TCMs. These findings are in agreement with previous studies involving human T cells (5) , thus providing the opportunity to selectively manipulate the function of the TEM subset that uses the Kv1.3-channel blocker PAP-1. This compound and the alternative Kv1.3-specific peptide blocker Shk(L5) were shown to inhibit the Kv1.3 current in activated TEMs and in resting naive T cells, respectively, which may at first suggest that Kv1.3-specific blockers inhibit the function of all T-cell subsets. However, although Kv1.3 channels dominate in all resting T-cell subsets, KCa3.1 channels are rapidly upregulated in naive cells and in TCMs upon activation. As such, these cells are no longer susceptible to Kv1.3 blockade while the TEM subset remains sensitive to its effects. Additional results from in vitro suppression assays showed that, although PAP-1 does suppress the proliferation of bulk PBMCs (IC 50 ¼ 1 lM) in RM, the inhibitory effect on CD28-depleted cells was clearly more potent, as indicated by the IC 50 of 100 nM, which is approximately 10-fold higher than that previously reported for human TEMs (10 nM; Ref. 7) . Since the assay in the previous study by Schmitz et al. (7) had utilized purified effector memory T cells and not PBMCs depleted of naive cells and TCMs, the effect of PAP-1 on isolated, CD28-depleted T cells in RM (as opposed to CD28depleted PBMCs) was also evaluated to determine if this was the cause of the difference. The IC 50 was approximately 350 nM (data not shown), which is greater than that initially obtained for the CD28-depleted PBMC fraction. This is not unexpected because a given number of purified TEMs would require a greater concentration of PAP-1 to be suppressed to the same extent as an equivalent number of the CD28-depleted PBMC fraction that would contain comparatively fewer TEMs. An in vivo setting is likely best reflected by the PBMC fraction. Regardless, the in vitro IC 50 of PAP-1 for TEMs of RM is still greater than that for isolated human TEMs. The reason for this difference remains unclear but given that the CD28-depleted cell fraction utilized in the assay was greater than 90% pure, purity issues are highly unlikely and intrinsic differences between TEMs in RM and in humans possibly contributed to the observed variation in the response to PAP-1. It is also possible that differences in the stimulus used in the previous and current study contributed to these dissimilarities. Nonetheless, the trend is importantly still maintained, with PAP-1 exerting a more potent suppressive effect on TEMs than on naive cells and TCMs in RM. The Kv1.3-channel expression pattern on TEMs in RM and the in vitro selectivity of PAP-1 for this T-cell subset provided a logical basis for pursuing in vivo studies. Upon confirmation of the safety and PK of PAP-1, a chronic dosing study was initiated and the moderately long half-life of 6.4 hrs allowed a trough level to be maintained with a single daily dose of 25 mg/kg. Although the trough levels achieved were considerably different in the two RM that were chronically administered PAP-1 (511 nM vs. 77 nM), these values are still within the normal range of physiologic variability (53) because of individual differences in absorption and/or rates of metabolism. Importantly, these trough levels indicate that in vivo non-toxic plasma concentrations of PAP-1 were achieved and were maintained near or greater than the level that was suppressive for TEMs in RM in vitro.
In addition to determining trough levels, the main purpose of the PAP-1 chronic dosing study was to demonstrate that PAP-1 selectively suppresses TEMs in vivo. Given that PAP-1 suppresses all TEMs and not only those specific for a particular antigen, it was also crucial to show that the suppression of this T-cell subset would not increase the host susceptibility to opportunistic infection and disease. This was especially important, because RM are carriers of CMV and reactivation of CMV replication due to an immunocompromised system has been documented and may lead to a serious illness (38) (39) (40) (41) (42) . Quantification of CMV DNA levels by real-time PCR in plasma samples from the two RM before and during chronic PAP-1 treatment indicated a detectable but low level of CMV in both animals even at baseline, which was unexpected. Elevated stress levels associated with repeated access to these RM for previous experiments and those conducted during the recent studies may be a contributing factor to this observation and may also be the reason for the fluctuations observed in CMV DNA levels during the early phase of PAP-1 application. A control of CMV replication was compromised as indicated by the rise in CMV DNA by Day 21. However, the observed increase in CMV DNA copies appears well below the levels reportedly associated with CMV-related illness in RM (43) . In a recent study, RM that were undergoing renal allotransplantation and that were administered large boluses of immunosuppressive drugs showed a 1-log-2-log increase in CMV titers without any signs of clinical disease (43) . Thus, the modest rise in CMV titers seen in our present study should only be considered a marker of reactivation and not a clinically significant event. Importantly, CMV DNA copy number decreased to levels near baseline following the discontinuation of PAP-1 treatment and no signs of illness were evident throughout the entire course of the study. These data therefore lend support to the selective suppressive effect of PAP-1 on TEMs in vivo because this T-cell subset has been described as largely responsibly for the control of CMV replication (26, 31) . The results also highlight the need for caution when pursuing a long-term dosing regimen because the extent of CMV reactivation needs to be taken into account.
In addition to the selective inhibitory effect of PAP-1 on TEMs, it was also important to demonstrate that the development or function of the central memory arm was not affected by PAP-1 in vivo. To achieve this, both RM were intranasally administered live, attenuated flu virus during PAP-1 treatment and the primary effector and secondary memory cell-mediated and humoral responses were compared before and after PAP-1 application was discontinued. Under normal circumstances of antigenic stimulation, the primary immune response typically involves the activation of naive cells that proliferate to produce cells that are at various stages of differentiation (18, 19) . Cells that are at a more terminally differentiated stage exert effector function, whereas those that are at an intermediate level of differentiation persist as TCMs after antigen clearance. Thus, following the initial flu immunization, naive cells will develop into flu-specific TEMs, but their further proliferation and function are expected to be inhibited by PAP-1 while the generation of TCMs should not be affected. Indeed, flow cytometric analyses that were performed 1, 2, and 3 weeks after immunization revealed a modest increase in TEM frequency in both RM (data not shown), and ICC assays also indicated no increase in the production of IFN-c, IL-2, or TNF-a from CD4 þ and CD8 þ T cells in response to the flu virus ( Fig. 6B; Day 28 ), which suggests a suppression of the primary effector T-cell response. After PAP-1 was discontinued, two flu boosters were administered to both RM to determine if the generation of central memory cells was affected by PAP-1. ICC data indicated that a stronger memory T cell response was exhibited by RWk7 than by RGq8. These cytokine responses were readily detectable and were comparable to or greater than those exhibited by historical controls that were also administered the flu virus but not treated with PAP-1. This suggests that a functional, secondary, flu-specific memory response was maintained and was exhibited by the PAP-1treated RM. Similarly, results from the ELISA showed a lack of flu-specific IgG production in the PAP-1-treated RM 3 weeks after the initial immunization, in contrast to the untreated RM, which clearly exhibited an antibody response. However, both PAP-1-treated RM exhibited a flu-specific IgG response after administration of a second flu booster, which suggests that the generation of central memory B cells was not affected. The secondary IgG response exhibited by RGq8 was again weaker than that of RWk7. Since RGq8 had maintained approximately 7-fold greater trough levels of PAP-1 than RWk7 (Table 4) , it is tempting to speculate that this may have been the reason for the minimal flu-specific response in this monkey. However, the response of a larger cohort of animals to PAP-1, including the parallel use of bona fide controls would need to be examined in order to derive a definite correlation between in vivo PAP-1 plasma concentrations and the suppression of antigen-specific immune responses.
The fact that the IgG responses were also influenced by PAP-1 raises the important point that PAP-1 affects not only a single cell subset (i.e., TEMs) but in fact also has an impact on B cells. Indeed, PAP-1 has been previously shown to inhibit the proliferation and function of classswitched IgD À CD27 þ B cells but not activated naive and IgD þ CD27 þ B cells (6) . This in combination with the suppressive effect of PAP-1 on CD4 þ TEMs with Th2 function may have contributed to the inhibition of the primary B-cell mediated IgG response. One may then posit how an IgG response was generated after the flu booster, given that PAP-1 should have suppressed memory classswitched B cells. Because PAP-1 does not affect the generation of IgD þ CD27 þ memory cells, it is possible that this compartment was able to undergo class switching after the booster immunizations. It would be of interest to evaluate the nature of the antibody response elicited when RM are immunized with flu boosters while still being administered PAP-1 to determine if antibody production would be limited to only IgM and not to IgG. These observations therefore stress the need for caution when interpreting results from the PAP-1 chronic dosing study, because its effect is exerted on not only a single cell subset but in fact influences both the cell-mediated and humoral arms of the immune system. It is also important to bear in mind that the nature and level of Kv1.3 expression in other major cell subsets, such as natural killer cells/natural killer T cells, has not been elucidated, although it has been suggested that components of the innate immune system are unaffected by Kv1.3 blockade (44) . A recent study demonstrated the presence of both Kv1.3 and Kv1.5 channels on human peripheral dendritic cells, which suggests that PAP-1 may also influence the function of this cell subset. However, the presence of the alternate potassium channel Kv1.5 may offset any inhibitory effect caused by PAP-1. The potential inhibitory effect of PAP-1 on other major cell lineages therefore remains to be clarified and the influence of this on disease outcome cannot be overlooked. However, worthy of mention is that the two RM that were undergoing chronic dosing of PAP-1 were not adversely affected by the live flu virus that normally replicates only in the upper respiratory tract and occasionally produces mild symptoms, such as transient nasal discharge, in healthy monkeys. Of note, such symptoms were not observed throughout the entire course of the study. Thus, the immune systems of the two RM in the study were not significantly compromised by PAP-1, at least during the short-term chronic dosing regimen.
In summary, the results from this study collectively show that the utilization of PAP-1 in RM is both safe and effective, which opens the door for PAP-1 use in SIVinfected RM to determine the effect of this small molecule on major cell lineages and to define those that play a major role in SIV pathogenesis. Future studies would therefore include administering PAP-1 to SIV-infected RM during the acute or chronic phase of infection to determine if the inhibition of TEM function prevents or slows disease progression to AIDS by limiting the number of viral cell targets and/or by muting the chronic immune hyperactivation exhibited by SIV-infected RM. Although the utilization of PAP-1 in an SIV-infected RM model particularly during the acute phase of infection may potentially limit the pool of viral target cells by inhibiting CD4 þ TEM function and proliferation, the effect on CD8 þ TEMs that assist in VL control cannot be overlooked. It is possible that, if a lower VL setting is achieved because of inhibition of CD4 þ TEMs, other cell lineages implicated in immune control, such as NK cells and B cells, may contribute to VL control, possibly bypassing the need for a rigorous CD8 þ TEM response. Because the effects of PAP-1 are almost immediately reversible, any detrimental effects on VL control can be relieved by discontinuing treatment or by lowering the dose. One may also test if the PAP-1 dose can be titrated to a concentration that perhaps maintains a balance between CD4 þ TEM inhibition and CD8 þ TEM function. In addition to the application of PAP-1 in RM, its use can also be applied in SIV-infected sooty mangabeys (SM), nonhuman primates that remain disease-free throughout the course of SIV infection (13, 45, 46) . The aim would be to determine the cause of disease resistance in this species and to evaluate if the inhibition of TEM function in SM results in disease development. Preliminary in vitro experiments performed by us have shown that the Kv1.3channel expression pattern in T cells of SM is very similar to that of T cells in RM and of human T cells. In addition, PAP-1 inhibits the Kv1.3 current, as shown by patchclamping experiments, and it also effectively suppresses the proliferation of both PBMCs and isolated TEM cells from SM in vitro (data not shown). The potential application for the use of PAP-1 in this nonhuman primate is therefore a reality, and these studies together with those involving RM are sure to further our understanding of the mechanisms involved in disease resistance and susceptibility in SIVinfected hosts. The observed differential expression of KCa3.1 channels in RM T-cells ( Fig. 2 ) and in T cells of SM (not shown) and the availability of the KCa3.1-specific blocker TRAM-34 (8) provide the opportunity to manipulate naive cells and central, memory cell subsets, which may prove to be beneficial during acute stages of infection. Further studies involving this additional potassium channel blocker therefore are warranted.
